for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boule Diagnostics AB

BOUL.ST

Latest Trade

43.40SEK

Change

0.55(+1.28%)

Volume

9,846

Today's Range

42.50

 - 

44.45

52 Week Range

37.45

 - 

104.60

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
42.85
Open
42.85
Volume
9,846
3M AVG Volume
1.19
Today's High
44.45
Today's Low
42.50
52 Week High
104.60
52 Week Low
37.45
Shares Out (MIL)
19.42
Market Cap (MIL)
832.00
Forward P/E
24.70
Dividend (Yield %)
1.28

Next Event

Q3 2019 Boule Diagnostics AB Earnings Release

Latest Developments

More

Boule Diagnostics Q2 Operating Profit Down At SEK 5.9 Million

Boule Diagnostics: Fredrik Dalborg Leaves Position As CEO

Boule Diagnostics Q1 Operating Profit Down At SEK 16.7 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boule Diagnostics AB

Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.

Industry

Medical Equipment & Supplies

Contact Info

Domnarsvgatan 4

+46.8.7447700

https://www.boule.com/

Executive Leadership

Peter von Ehrenheim

Independent Chairman of the Board

Fredrik Dalborg

President, Chief Executive Officer

Christina Rubenhag

Chief Financial Officer, Senior Vice President

Fredrik Ekdahl

Senior Vice President Research & Development

Michael Elliott

Senior Vice President Research & Development at CDS

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2017

0.4K

2018

0.4K

2019(E)

0.5K
EPS (SEK)

2017

1.918

2018

2.110

2019(E)

1.735
Price To Earnings (TTM)
38.82
Price To Sales (TTM)
1.83
Price To Book (MRQ)
2.74
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
50.41
LT Debt To Equity (MRQ)
17.35
Return on Investment (TTM)
6.03
Return on Equity (TTM)
4.28

Latest News

BRIEF-Boule Diagnostics Receives Warning Letter From US FDA Authority

* SAID ON FRIDAY UNIT BOULE MEDICAL RECEIVED A WARNING LETTER FROM THE US FOOD AND DRUG ADMINISTRATION

BRIEF-Boule Diagnostics Unit Buys New Technologies From Drew Scientific

* UNIT BOULE MEDICAL AB BUYS NEW TECHNOLOGIES FROM DREW SCIENTIFIC, INC.

BRIEF-Boule Diagnostics Q4 Operating Profit Rises To SEK ‍14.9​ Million

* Q4 NET SALES SEK 107.2 MILLION VERSUS SEK 104.6 MILLION YEAR AGO

BRIEF-Boule Diagnostics Q3 operating profit grows to SEK ‍28.2​ mln

* Q3 NET SALES SEK 109.7 MILLION VERSUS SEK 108.5 MILLION YEAR AGO

BRIEF-Boule Diagnostics appoints ‍christina Rubenhag new CFO

* CHRISTINA RUBENHAG NEW CFO FROM OCT.9 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Boule Diagnostics Q2 net result swings to loss SEK 1.1 mln

* Q2 NET SALES SEK 104.3 MILLION VERSUS SEK 102.0 MILLION YEAR AGO

BRIEF-Boule Diagnostics closes factory in China

* BOULE DIAGNOSTICS OPTIMIZES MANUFACTURING STRUCTURE - CLOSES FACTORY IN CHINA

BRIEF-Boule Diagnostics Q1 operating profit rises to SEK 12.0 mln

* Q1 NET SALES SEK 106.6 MILLION VERSUS SEK 84.4 MILLION YEAR AGO

BRIEF-Boule Diagnostics wins strategic contract

* Installation of instruments will begin in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Boule Diagnostics Q4 operating profit grows to SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($11.89 million) versus 88.4 million crowns year ago

BRIEF-Boule Diagnostics Q4 operating profit up at SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($12 million)versus 88.4 million crowns year ago

BRIEF-Boule Diagnostics presents new targets, adjusts dividend policy

* Said on Wednesday had revised its financial targets and adjusted dividend policy

BRIEF-Boule Diagnostics wins new contract in India

Boule Diagnostics AB : * Wins new procurement in India * Systems will be delivered during first quarter of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tredje AP-fonden buys 7.6 pct stake in Boule Diagnostics

* Says Tredje AP-fonden buys 358,068 shares in Boule Diagnostics AB corresponding to 7.6 percent stake

BRIEF-Boule Diagnostics names Fredrik Dalborg new CEO

* Dalborg to replace Ernst Westman, who will leave CEO post and company in Q1 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Boule Diagnostics Q3 operating profit up at SEK 24.8 mln

* Q3 net sales 108.5 million Swedish crowns ($12 million)versus 88.8 million crowns year ago

BRIEF-Boule Diagnostics wins assignment from Red Cross in Kenya

* Wins assignment from Red Cross in Kenya Source text for Eikon:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up